Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

6 Jun 2018 07:00

RNS Number : 4052Q
Instem plc
06 June 2018
 

6 June 2018

Instem plc

("Instem")

 

Contract win

 

Leading Fortune 500 Company adopts Instem's Samarind RMS solution for its worldwide medical products regulatory tracking system

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that a leading Fortune 500 medical products and pharmaceuticals company has adopted Instem's Samarind RMS Software-as-a-Service ("SaaS") solution. The contract is worth approximately US$750,000 incorporating both perpetual license and SaaS revenue streams with c. 80% of the contract value being recognised in 2018 and annual recurring revenue of US$169,000.

 

Samarind RMS provides medical device and pharmaceutical companies with a smarter way to manage their Product Information, facilitating initial marketing authorisation and supporting ongoing regulatory compliance. The product is optimised to enable these companies to register and track their regulated products worldwide by maintaining a single integrated database of all relevant information, which is then used to update regulators as products change over time. The comprehensive functionality provided by Samarind RMS enables customers to systematically define and execute complex regulatory activities across a globally dispersed workforce whilst providing a single place to find, analyse and act on a wealth of product and regulatory information.

 

Phil Reason, CEO of Instem plc, said: "This contract win with a global company, which ranks among the top 25 on the Fortune 500, continues the good momentum experienced with our regulatory information management solutions 2017 to date and particularly Instem's success in the medical device field. We are very pleased to be delivering this as a SaaS agreement."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

 

 

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFKPDKABKDAAK
Date   Source Headline
26th Jan 20073:07 pmRNSAcquisition of stake in INS
18th Dec 20063:09 pmRNSTotal Voting Rights
26th Sep 20067:00 amRNSInterim Results
30th Aug 20064:05 pmRNSNotice of Results
17th Jul 20063:21 pmRNSRe Contract
27th Jun 20063:53 pmRNSDirectors Dealings
6th Jun 20062:47 pmRNSDirector/PDMR Shareholding
5th Jun 20063:51 pmRNSHolding(s) in Company
2nd Jun 20064:49 pmRNSDirectors. dealings
2nd Jun 20064:48 pmRNSDirectors. dealings
1st Jun 20067:01 amRNSSellafield Agreement
31st May 200610:48 amRNSFirst Day of Dealings
4th Aug 20059:39 amRNSCompulsory Acquisition
29th Jul 200511:38 amRNSHolding(s) in Company
8th Jul 20054:36 pmRNSBoard Changes and Delisting
8th Jul 20057:00 amRNSOffer for Infast Group Update
6th Jul 20057:01 amRNSOffer for Infast Group Update
28th Jun 20055:27 pmRNSOffer for Infast Group Update
20th Jun 20057:01 amRNSOffer for Infast Group Update
31st May 20054:30 pmRNSRule 8.4- Infast Group PLC
31st May 20059:57 amRNSRule 8.3- Infast Group PLC
27th May 20055:12 pmRNSOffer Document Posted-Amend
27th May 20053:58 pmRNSOffer Document Posted
26th May 20057:02 amRNSRecom. Offer for Infast Group
10th May 200512:48 pmRNSEPT Disclosure
9th May 200510:32 amRNSEPT Disclosure
4th May 200511:06 amRNSEPT Disclosure
29th Apr 200510:31 amRNSResult of AGM
28th Apr 20058:45 amRNSAGM Statement
26th Apr 200511:42 amRNSEPT Disclosure
26th Apr 200511:16 amRNSRule 8.3- Infast Group PLC
25th Apr 200512:00 pmRNSEPT Disclosure
22nd Apr 200511:25 amRNSEMM Disclosure
21st Apr 20053:36 pmRNSDisposal
20th Apr 200510:27 amRNSEMM Disclosure
14th Apr 20059:40 amRNSRule 8 - Infast Group PLC
13th Apr 20053:00 pmRNSRule 2.10 Announcement
13th Apr 200512:20 pmRNSStatement re Possible Offer
12th Apr 200510:04 amRNSHolding(s) in Company
8th Apr 20052:19 pmRNSHolding(s) in Company
7th Apr 20055:12 pmRNSHolding(s) in Company
3rd Mar 20057:01 amRNSFinal Results
15th Feb 20052:32 pmRNSDisposal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.